Gastric protection in cardiological practice: an Italian survey on the prescriptive attitude.

IF 1.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Minerva cardiology and angiology Pub Date : 2024-02-01 DOI:10.23736/S2724-5683.23.06438-4
Salvatore E Aragona, Alberto Margonato, Salvatore Felis, Mario Crisci, Giorgio Ciprandi
{"title":"Gastric protection in cardiological practice: an Italian survey on the prescriptive attitude.","authors":"Salvatore E Aragona, Alberto Margonato, Salvatore Felis, Mario Crisci, Giorgio Ciprandi","doi":"10.23736/S2724-5683.23.06438-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastric protection is commonly considered in patients who use medications able to damage gastric mucosa, mainly NSAIDs, antiplatelets, and anticoagulants. Therefore, cardiologists may frequently prescribe drugs to protect the stomach from damaging medications. The present survey investigated the attitude toward using gastric protection by a panel of Italian cardiologists.</p><p><strong>Methods: </strong>A self-administered questionnaire included three sections concerning practical problems on this issue in clinical practice facing patients with cardiological disorders. The questionnaire was administered in three successive months.</p><p><strong>Results: </strong>Ninety Italian cardiologists completed the questionnaire. They all consider gastric protection, mainly when prescribing potentially noxious medications. Usually, cardiologists prescribe proton pump inhibitors (PPIs) in 60% of their patients. Alginates and mucosal protectors are less considered. As a rule, cardiologists request investigations if the initial treatment fails. Moreover, the safety issue is carefully assessed. Furthermore, this survey experience significantly affected the approach to managing patients who require gastric protection. The participants carefully considered the prescriptive appropriateness of gastric protectors, mainly concerning the PPIs use. Consequently, PPIs were discontinued when inappropriate. A new medical device with triple action (antacid, mucosal protectors, and anti-reflux) contributed to this new attitude.</p><p><strong>Conclusions: </strong>The present survey underscored that the appropriateness in prescribing gastric protectors is clinically relevant. In addition, a longitudinal survey experience contributed to change the practical approach by highlighting the prescriptive appropriateness of PPIs, and using a new medical device with multiple gastroprotective activities.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":"72 1","pages":"56-66"},"PeriodicalIF":1.3000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva cardiology and angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2724-5683.23.06438-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Gastric protection is commonly considered in patients who use medications able to damage gastric mucosa, mainly NSAIDs, antiplatelets, and anticoagulants. Therefore, cardiologists may frequently prescribe drugs to protect the stomach from damaging medications. The present survey investigated the attitude toward using gastric protection by a panel of Italian cardiologists.

Methods: A self-administered questionnaire included three sections concerning practical problems on this issue in clinical practice facing patients with cardiological disorders. The questionnaire was administered in three successive months.

Results: Ninety Italian cardiologists completed the questionnaire. They all consider gastric protection, mainly when prescribing potentially noxious medications. Usually, cardiologists prescribe proton pump inhibitors (PPIs) in 60% of their patients. Alginates and mucosal protectors are less considered. As a rule, cardiologists request investigations if the initial treatment fails. Moreover, the safety issue is carefully assessed. Furthermore, this survey experience significantly affected the approach to managing patients who require gastric protection. The participants carefully considered the prescriptive appropriateness of gastric protectors, mainly concerning the PPIs use. Consequently, PPIs were discontinued when inappropriate. A new medical device with triple action (antacid, mucosal protectors, and anti-reflux) contributed to this new attitude.

Conclusions: The present survey underscored that the appropriateness in prescribing gastric protectors is clinically relevant. In addition, a longitudinal survey experience contributed to change the practical approach by highlighting the prescriptive appropriateness of PPIs, and using a new medical device with multiple gastroprotective activities.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心脏病学实践中的胃保护:意大利关于规范态度的调查。
背景:使用会损伤胃黏膜的药物(主要是非甾体抗炎药、抗血小板药和抗凝剂)的患者通常会考虑保护胃部。因此,心脏病专家可能会经常处方保护胃免受药物损伤的药物。本调查调查了意大利心脏病专家小组对使用护胃药物的态度:自填式问卷包括三个部分,涉及心脏病患者在临床实践中遇到的实际问题。结果:90 名意大利心脏病学家接受了问卷调查:结果:90 名意大利心脏病专家完成了问卷调查。他们都考虑到了胃保护问题,主要是在处方潜在毒性药物时。通常,心脏病专家会给 60% 的患者开质子泵抑制剂 (PPI)。藻酸盐和粘膜保护剂则较少考虑。通常,如果初始治疗失败,心脏病专家会要求进行检查。此外,还会仔细评估安全性问题。此外,这次调查的经验极大地影响了管理需要胃保护患者的方法。参与者仔细考虑了胃保护剂的处方适当性,主要是关于 PPIs 的使用。因此,在不适当的情况下,会停用 PPIs。一种具有三重作用(抗酸剂、粘膜保护剂和抗反流)的新型医疗设备促成了这种新的态度:本调查强调了胃保护剂处方的适当性与临床相关。此外,纵向调查的经验通过强调 PPIs 处方的适当性和使用具有多重胃保护作用的新型医疗设备,有助于改变实际做法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Minerva cardiology and angiology
Minerva cardiology and angiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.60
自引率
18.80%
发文量
118
期刊最新文献
Lipid-lowering therapies: the arrows in the quiver and future bullets. Presepsin as a biomarker of coronary artery disease in type 2 diabetes along the immune-inflammatory continuum. Bridging cardiology and neurorehabilitation: toward integrated recovery after acute and chronic cardiac events. Use of vericiguat in a patient with heart failure with reduced ejection fraction and transthyretin cardiac amyloidosis: a helpful therapeutic opportunity. A new tool for risk stratification in transcatheter aortic valve intervention.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1